HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bendazac

Also Known As:

bendazolic acid; bendazolic acid, sodium salt; bindazac; 1-benzylindazole-3-oxyacetic acid

Networked: 31 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - Indazoles: 179
        bendazac: 31
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 179
      - bendazac: 31

Experts

1.	Nie, Jing: 1 article (03/2022)
2.	Sun, Lei: 1 article (03/2022)
3.	Wang, Dongbo: 1 article (03/2022)
4.	Wang, Xuejian: 1 article (03/2022)
5.	Wu, Huina: 1 article (03/2022)
6.	Wu, Jiyong: 1 article (03/2022)
7.	Zhang, Di: 1 article (03/2022)
8.	Adam, Klaus-Peter: 1 article (04/2013)
9.	Alexander, Danny C: 1 article (04/2013)
10.	Guo, Lining: 1 article (04/2013)

Related Diseases

1.	Necrosis 04/01/2013 - "To gain insights on DILI pathogenesis and identify potential biomarkers for improved DILI detection, we performed untargeted metabolomic analyses on rats treated with thirteen known hepatotoxins causing various types of DILI: necrosis (acetaminophen, bendazac, cyclosporine A, carbon tetrachloride, ethionine), cholestasis (methapyrilene and naphthylisothiocyanate), steatosis (tetracycline and ticlopidine), and idiosyncratic (carbamazepine, chlorzoxasone, flutamide, and nimesulide) at two doses and two time points. "
2.	Cholestasis 04/01/2013 - "To gain insights on DILI pathogenesis and identify potential biomarkers for improved DILI detection, we performed untargeted metabolomic analyses on rats treated with thirteen known hepatotoxins causing various types of DILI: necrosis (acetaminophen, bendazac, cyclosporine A, carbon tetrachloride, ethionine), cholestasis (methapyrilene and naphthylisothiocyanate), steatosis (tetracycline and ticlopidine), and idiosyncratic (carbamazepine, chlorzoxasone, flutamide, and nimesulide) at two doses and two time points. "
3.	Cataract (Cataracts) 01/01/1986 - "The final conclusion of our study is that bendazac at a dosage ten-fold lower than that used in the clinics is anticataract drug when orally administered to "BLOA test selected" patients, at least for short term treatment of young, otherwise healthy humans with cortical cataract." 01/01/1989 - "4. Improvement of lens opacity (bendazac). " 08/01/1988 - "These results are discussed in relation to the use of bendazac as an anti-cataract drug." 01/01/1983 - "The mechanism of the protective action of bendazac against lens protein denaturation is discussed together with the implications of such protective action in the treatment of cataract." 04/10/1982 - "Pilot study of bendazac for treatment of cataract."
4.	Skin Diseases (Skin Disease) 05/01/1970 - "[Clinical considerations on a controlled trial of bendazolic acid in some dermatoses]." 04/01/1970 - "[Use of bendazolic acid in skin diseases in childhood]." 06/01/1969 - "[Clinical observations on the local anti-inflammatory action of a new drug (bendazolic acid) in skin diseases in childhood]." 05/01/1971 - "[Bendazolic acid in the therapy of some dermatoses. "
5.	Acute Liver Failure (Fulminant Hepatic Failure) 03/18/1995 - "[Fulminant liver failure due to bendazac]." 03/18/1995 - "[Fulminant liver failure due to bendazac]."

Related Drugs and Biologics

1.	Acetaminophen (Paracetamol)
2.	Cyclosporine (Ciclosporin)
3.	Biomarkers (Surrogate Marker)
4.	Ticlopidine (Ticlid)
5.	Tetracycline (Achromycin)
6.	Methapyrilene
7.	Flutamide (Eulexin)
8.	Ethionine
9.	Carbon Tetrachloride (Tetrachloromethane)
10.	Carbamazepine (Tegretol)

Related Therapies and Procedures

1.	Therapeutics
2.	Lenses
3.	Oral Administration